Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : News Center....FLASH!!!!! -- Ignore unavailable to you. Want to Upgrade?

To: Instock who wrote (26)	12/28/1997 9:06:00 PM
From: username	Respond to of 115

OK Instock! All: please see ASND thread (28748) re: CPQ. could be a play tomorrow. if I knew how to transfer the message, I would. sorry, I'm semi-literate.pete

To: Instock who wrote (26)	12/29/1997 5:51:00 AM
From: Dale Baker	Respond to of 115

JNJ - I don't follow this stock, but this story could have an impact on Monday: yahoo.com

To: Instock who wrote (26)	12/29/1997 9:01:00 AM
From: Milk	Read Replies (2) \| Respond to of 115

Watson Pharmaceuticals (NYSE: WPI) Announces FDA Approval for Etodolac Capsules CORONA, Calif., Dec. 29 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI - news) announced today that its wholly owned subsidiary, Royce Laboratories, Inc., has received approval from the Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) to manufacture and market Etodolac 200mg and 300mg capsules. Etodolac is the off-patent equivalent of Wyeth-Ayerst Laboratories' Lodine(R), which is a nonsteroidal anti-inflammatory drug used for the treatment of osteoarthritis and for the management of pain. Shipments are expected to begin in January 1998. Source: biz.yahoo.com